Skip to main content
Premium Trial:

Request an Annual Quote

Galileo and First Genetic Trust Collaborate for Pharmacogenomics Services

NEW YORK, June 10 - First Genetic Trust, of Chicago, and Galileo Genomics are collaborating to provide pharmacogenomics services to pharma and biotech, the companies said today.

 

"The US FDA is on the threshold of creating a regulatory framework to   allow pharmacogenomics to better treat individuals through improved drug development. The combined assets of First Genetic Trust and Galileo will allow us to assist the pharmaceutical industry to develop safer and more effective drugs," said Dr. John Hooper, CEO of Galileo Genomics, said in a statement.

 

In the collaboration, Galileo, of Montreal, will provide data from patients in the Quebecfounder population and others, as well as its high-throughput genotyping, bioinformatics, and statistical analysis capabilities.

First Genetic Trust will contribute its enTrust genetic banking platform, as well as the channels it has established for recruiting patients in the US for large-scale studies to validate discoveries made in the founder populations. The company, based in Chicagowill also include its computational genomics capabilities, including its genetic pattern discovery and data mining tools.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.